Reuters logo
FDA panel recommends approval of Novo's degludec insulin
November 8, 2012 / 10:13 PM / 5 years ago

FDA panel recommends approval of Novo's degludec insulin

Nov 8 (Reuters) - An advisory panel to the U.S. Food and Drug Administration on Thursday voted to recommend approval of Danish drugmaker Novo Nordisk’s new ultra-long-acting insulin degludec, despite signals of possible cardiovascular risk.

The panel of outside medical experts unanimously recommended that the company undertake a large “outcomes” study to verify heart safety of the once-daily drug.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below